Dr.Ta-Ching Chen Taiwan

Dr. Ta-Ching Chen received his MD and Ph.D. from National Taiwan University and completed his ophthalmic residency and fellowship training at National Taiwan University Hospital (NTUH). He is currently an Associate Professor in the Department of Ophthalmology and serves as the Executive Secretary of the Center for Frontier Medicine at NTUH. In recent years, Dr. Chen's team has focused on ocular neurodegeneration, publishing over 50 original SCI articles in recent 5 years. Following his international fellowship at Massachusetts Eye and Ear (MEE), Harvard Medical School, where he specialized in inherited retinal degeneration, ocular genetics, and gene therapy, Dr. Chen established an integrated clinical service for molecular and imaging-based diagnostics. By carefully integrating genetic, poly-omics, and clinical data, his team has published numerous studies in prestigious journals, including Nature Communications, NPJ Genomic Medicine, IOVS, Clinical and Experimental Ophthalmology, and Eye. Dr. Chen also performed Taiwan's first retinal gene therapy microsurgery on a patient with RPE65 mutation in 2021 and recently completed a Phase II/III clinical trial for Stargardt disease in 2024. Dr. Chen's research team also pursues advancements in stem cell therapy and bioengineering for optic neuropathy. He holds patents for biocompatible scaffolds that support iPSC-derived retinal ganglion cells, offering potential applications in optic nerve regeneration. His team's work in this area has been published in journals like Advanced Science, Advanced Healthcare Materials, IOVS, and JTICE. These efforts have been recognized with several awards, including the Ta-You Wu Memorial Award in 2021, the NTUH Outstanding Research Award in 2024, and the Dean Chen-Yuan Lee Memorial Award in Medicine in 2025.